A comparative review of current topical antibiotics for impetigo
| Autor: | Adelaide A. Hebert, Eugenio Galindo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Retapamulin
medicine.medical_specialty Impetigo Topical antibiotics Mupirocin 030204 cardiovascular system & hematology Administration Cutaneous Drug Costs 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Drug Resistance Bacterial Humans Medicine Pharmacology (medical) Child skin and connective tissue diseases Randomized Controlled Trials as Topic integumentary system business.industry General Medicine medicine.disease Dermatology Anti-Bacterial Agents Bacterial skin diseases Treatment Outcome chemistry 030220 oncology & carcinogenesis Ozenoxacin business Pediatric population |
| Zdroj: | Expert Opinion on Drug Safety. :1-7 |
| ISSN: | 1744-764X 1474-0338 |
| DOI: | 10.1080/14740338.2021.1902502 |
| Popis: | Impetigo is a superficial bacterial skin infection largely affecting the pediatric population. The objective of this review is to provide a comparison of mechanism of action, efficacy and safety of the available topical antibiotics for impetigo.Randomized clinical trials that evaluated the use of topical antibiotics for treatment of impetigo were included. Two thousand eighty-nine studies were initially identified, and five randomized clinical trials met the criteria for further analysis.Topical antibiotics had greater resolution of impetigo in comparison to vehicle in these pivotal clinical trials. Adverse events were minimal, with the most common being pruritus at the application site. Cost or insurance coverage may be a limiting factor in choosing the best therapeutic agent, with mupirocin ointment having the lowest cost. Mupirocin has shown clinical efficacy against MRSA but a bacterial culture is recommended to rule out resistance. Ozenoxacin and retapamulin are effective alternatives but may entail higher cost. Retapamulin is indicated for lesions of impetigo that are colonized by MSSA and streptococcus S. pyogenes but not MRSA based on clinical efficacy of phase III trials. Fusidic acid, available in other countries, is a non-FDA approved medication although rising resistance rates represent a growing concern. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|